MABD51
抗-Brn-2 （POU3F2）抗体，克隆8C4.2
clone 8C4.2, from mouse
别名:
POU domain, class 3, transcription factor 2, Brain-specific homeobox/POU domain protein 2, Brain-2, Brn-2, Nervous system-specific octamer-binding transcription factor N-Oct-3, Octamer-binding protein 7, Oct-7, Octamer-binding transcription factor 7, OTF
登录查看公司和协议定价
所有图片(3)
About This Item
UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41
生物来源
mouse
质量水平
抗体形式
purified immunoglobulin
抗体产品类型
primary antibodies
克隆
8C4.2, monoclonal
种属反应性
rat, human
技术
immunohistochemistry: suitable (paraffin)
western blot: suitable
同位素/亚型
IgG1κ
NCBI登记号
UniProt登记号
运输
wet ice
靶向翻译后修饰
unmodified
基因信息
human ... POU3F2(5454)
一般描述
Brn-2 （POU结构域，第3类，转录因子2; Oct-7; N-Oct-3; 或POU3F2）是POU 结构域转录因子大家族的成员。 高度同源的POU结构域包含N末端的一个POU特定结构域，C末端的一个POU同源结构域，以及一个互联连接子区。POU 结构域连接 DNA 序列 5’-ATGCAAAT-3’。Brn-2 在发育中的CNS中高度表达，并可能在神经形成，特别是下丘脑的发育中起一定作用。过去的研究也表明 Brn-2 可以整合 BRAF/MAP 激酶和Wnt/β-联蛋途径下游的信号，Brn-2 可能涉及黑色素瘤的转化和增殖。
免疫原
GST标记的重组蛋白，对应于人Brn-2 (POU3F2)。
应用
免疫组化分析：代表性批次的1：50稀释液可在正常大鼠脑组织、浦肯野细胞、篮细胞、大鼠小脑组织的神经胶质细胞、大鼠小脑组织的神经元、大鼠额叶皮层的神经元和神经胶质细胞以及人脑桥组织的神经元中检测Brn-2。
抗-Brn-2（POU3F2）抗体（克隆8C4.2）可检测Brn-2 （POU3F2）水平，&已发布&经验证可用于蛋白质印迹、IHC(P)。
质量
通过蛋白质印迹法在 SK-N-MC 细胞裂解液中进行了评估。
蛋白质印迹分析：该抗体的1：2,000稀释液在10 µg SK-N-MC细胞裂解液中检测到Brn-2 (POU3F2)。
蛋白质印迹分析：该抗体的1：2,000稀释液在10 µg SK-N-MC细胞裂解液中检测到Brn-2 (POU3F2)。
目标描述
观测值〜54 kDa。
计算分子量为47 kDa，Brn-2（POU3F2）在一些细胞裂解液中观测值为~50-55 kDa（Wolfe, A., et al., (2002).Molecular Endocrinology.16(3):435-449)。
计算分子量为47 kDa，Brn-2（POU3F2）在一些细胞裂解液中观测值为~50-55 kDa（Wolfe, A., et al., (2002).Molecular Endocrinology.16(3):435-449)。
外形
形式：纯化
分析说明
对照
SK-N-MC细胞裂解液
SK-N-MC细胞裂解液
Not finding the right product?
Try our 产品选型工具.
WGK
WGK 1
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Meitetsu Masawa et al.
The American journal of pathology, 192(6), 847-861 (2022-04-04)
Although recent reports have revealed the importance of the inactivation of both RB1 and TP53 in the transformation from lung adenocarcinoma into neuroendocrine carcinoma (NEC), the requirements for complete transformation into NEC have not been elucidated. To investigate alterations in
Zhongyuan Bao et al.
Oxidative medicine and cellular longevity, 2021, 6338722-6338722 (2021-12-03)
Traumatic brain injury (TBI) causes a high rate of mortality and disability, and its treatment is still limited. Loss of neurons in damaged area is hardly rescued by relative molecular therapies. Based on its disease characteristics, we transplanted human embryonic
Yilin Feng et al.
STAR protocols, 4(3), 102346-102346 (2023-07-08)
In glioma modeling, existing organoid protocols lack the ability to replicate glioma cell invasion and interaction with normal brain tissue. Here, we present a protocol for generating in vitro brain disease models using human-induced pluripotent- or embryonic-stem-cell-derived cerebral organoids (COs). We
Waseem K Raja et al.
PloS one, 17(12), e0277532-e0277532 (2022-12-02)
There are currently no preventive or disease-modifying therapies for Parkinson's Disease (PD). Failures in clinical trials necessitate a re-evaluation of existing pre-clinical models in order to adopt systems that better recapitulate underlying disease mechanisms and better predict clinical outcomes. In
Aaron Gordon et al.
Nature neuroscience, 24(3), 331-342 (2021-02-24)
Human stem-cell-derived models provide the promise of accelerating our understanding of brain disorders, but not knowing whether they possess the ability to mature beyond mid- to late-fetal stages potentially limits their utility. We leveraged a directed differentiation protocol to comprehensively
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门